Novo Nordisk Pushes Buyback Past 33 Million Shares as Rebrand, Milan Data and London Strategy Day Converge

Novo Nordisk plans 44 EASD abstracts and a London strategy day, as buybacks top 33 million B-shares and Ziltivekimab trials halt.

Novo Nordisk has spent the past week laying out a dense calendar of corporate and scientific events, even as its equity continues to trade well below where it started the year. The Danish drugmaker now finds itself juggling a rebrand, an accelerating capital return programme and a pair of high-stakes appearances in Milan and London — all while absorbing a clinical setback outside its core franchise.

At the top of the agenda is the European Association for the Study of Diabetes (EASD) 2026 congress, running from 28 September to 2 October in Milan. Novo Nordisk confirmed it will put 44 abstracts before the specialist audience, spanning real-world data on the oral formulation of its weight-loss drug Wegovy, fresh findings on CagriSema and next-generation amylin therapies. An international press briefing has been scheduled for 30 September to walk through the results in detail.

Capital Markets Day Follows Close Behind

Just three weeks before the Milan gathering, on 21 September, management will host a Capital Markets Day in London. The event is billed as a comprehensive update on the group's revised strategy, and market watchers are keen to see how the company intends to defend and extend its leading position in the lucrative obesity and diabetes treatment market over the medium term.

The two appearances sit alongside a broader corporate reset. On Monday, Novo Nordisk unveiled a brand overhaul under which it will operate simply as "Novo," paired with a reworked corporate culture branded "The Novo Way." CEO Mike Doustdar reinforced the message on Tuesday, urging staff to adopt a more customer-focused mindset as the company looks to claw back ground lost in the obesity drug market, according to a Reuters report.

Buyback Programme Tops 33 Million B-Shares

On the capital return front, the company disclosed Monday that it had repurchased a total of 33,084,179 B-shares under its ongoing programme through 11 September. Since the scheme began on 4 February 2026, Novo Nordisk has paid an average of 281.89 DKK per share, putting the cumulative transaction volume at exactly 9,326,186,478 DKK.

Trading has been steadier of late. The stock changed hands at EUR 36.54 on the day of the buyback update, a modest gain of 0.3%, while pre-market indications on another session put the shares at EUR 36.48. The bigger picture remains challenging for shareholders: the equity is down 17% year-to-date and sits 34% below its 52-week high of EUR 54.86.

Cardiovascular Setback Sharpens Focus on GLP-1 Franchise

Pressure on the leadership has mounted as diversification beyond diabetes and obesity has proven harder to deliver than planned. On 7 September, Novo Nordisk halted both Phase 3 trials of its experimental cardiovascular drug Ziltivekimab — HERMES and ATHENA — after an independent data monitoring committee concluded there was a low likelihood of a clinically meaningful benefit in either study.

That development stop dented hopes of quickly building new pillars outside the established GLP-1 portfolio, raising the stakes on defending the core business against rivals while opening up new indications for proven compounds.

Progress on that front has not been absent. Chinese regulators granted Wegovy approval on 10 September for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — the first green light for a GLP-1 receptor agonist in this severe liver disease in the Chinese market. Two days earlier, on 7 September, the company released late-stage study data on semaglutide showing that, after 68 weeks of treatment, 40.4% of participating children aged 6 to under 12 with full adherence to therapy were no longer classified as obese.

Taken together, the developments make clear that near-term earnings power still rests primarily on market penetration and indication expansion within the GLP-1 family, while the executive team works in parallel to sharpen its internal competitive edge. The pipeline data due in Milan and the strategic blueprint promised in London now carry outsized weight in rebuilding investor confidence.